Article first published online: 26 JUL 2007
Copyright © 2007 American Association for the Study of Liver Diseases
Volume 46, Issue 3, pages 666–671, September 2007
How to Cite
Tseng, F.-C., O'Brien, T. R., Zhang, M., Kral, A. H., Ortiz-Conde, B. A., Lorvick, J., Busch, M. P. and Edlin, B. R. (2007), Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology, 46: 666–671. doi: 10.1002/hep.21765
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Potential conflict of interest: Nothing to report.
- Issue published online: 24 AUG 2007
- Article first published online: 26 JUL 2007
- Manuscript Accepted: 9 APR 2007
- Manuscript Received: 21 JUL 2006
- Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics
- Federal funds from National Cancer Institute contracts. Grant Numbers: NO1-CO-12400, N02-CP-91027
- Urban Health Study. Grant Number: R01-DA13245
- NIH. Grant Number: R01-DA16159
- Center for Substance Abuse Treatment. Grant Number: H79-TI12103
- City and County of San Francisco Department of Public Health
- 14The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980., .
- 15Categorical data analysis using the SAS® system. 2nd ed. Cary, NC: SAS Institute; 2000., , .
- 20Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 9123–30., , , et al.
- 23What is the evidence for the effectiveness of interventions to reduce hepatitis C infection and the associated morbidity? A Health Evidence Network Report. Copenhagen: WHO, 2005. Available at: http://www.euro.who.int/document/E86159.pdf; accessed May 7, 2007., , .